Published in Alzheimers Res Ther on October 17, 2013
Functional connectivity in autosomal dominant and late-onset Alzheimer disease. JAMA Neurol (2014) 2.28
Alzheimer's disease genetics: from the bench to the clinic. Neuron (2014) 1.65
Symptom onset in autosomal dominant Alzheimer disease: a systematic review and meta-analysis. Neurology (2014) 1.47
iPS cell technologies: significance and applications to CNS regeneration and disease. Mol Brain (2014) 1.14
Tau and neurodegenerative disease: the story so far. Nat Rev Neurol (2015) 1.10
CAP-advancing the evaluation of preclinical Alzheimer disease treatments. Nat Rev Neurol (2015) 1.05
Amyloid-beta protein clearance and degradation (ABCD) pathways and their role in Alzheimer's disease. Curr Alzheimer Res (2015) 0.98
Advances in the prevention of Alzheimer's Disease. F1000Prime Rep (2015) 0.89
Proof of concept demonstration of optimal composite MRI endpoints for clinical trials. Alzheimers Dement (N Y) (2016) 0.84
Precision medicine: Clarity for the clinical and biological complexity of Alzheimer's and Parkinson's diseases. J Exp Med (2015) 0.83
Imaging as a biomarker in drug discovery for Alzheimer's disease: is MRI a suitable technology? Alzheimers Res Ther (2014) 0.81
Cerebrospinal fluid analysis in Alzheimer's disease: technical issues and future developments. J Neurol (2014) 0.81
Evaluation of a Genetic Risk Score to Improve Risk Prediction for Alzheimer's Disease. J Alzheimers Dis (2016) 0.81
Endpoints for Pre-Dementia AD Trials: A Report from the EU/US/CTAD Task Force. J Prev Alzheimers Dis (2015) 0.81
Genetic diagnosis and prognosis of Alzheimer's disease: challenges and opportunities. Expert Rev Mol Diagn (2015) 0.79
δ-COP modulates Aβ peptide formation via retrograde trafficking of APP. Proc Natl Acad Sci U S A (2016) 0.79
Autosomal Dominant Alzheimer Disease: A Unique Resource to Study CSF Biomarker Changes in Preclinical AD. Front Neurol (2015) 0.77
A survey of attitudes toward clinical trials and genetic disclosure in autosomal dominant Alzheimer's disease. Alzheimers Res Ther (2015) 0.76
Endpoints in preclinical Alzheimer's disease trials. J Clin Psychiatry (2014) 0.76
Combined immunotherapy with "anti-insulin resistance" therapy as a novel therapeutic strategy against neurodegenerative diseases. NPJ Parkinsons Dis (2017) 0.75
Tau protein as a target for Alzheimer's disease management. Saudi Pharm J (2015) 0.75
The DIAN-TU Next Generation Alzheimer's prevention trial: Adaptive design and disease progression model. Alzheimers Dement (2016) 0.75
A Novel Study Paradigm for Long-term Prevention Trials in Alzheimer Disease: The Placebo Group Simulation Approach (PGSA): Application to MCI data from the NACC database. J Prev Alzheimers Dis (2014) 0.75
Presymptomatic cortical thinning in familial Alzheimer disease: A longitudinal MRI study. Neurology (2016) 0.75
APP, PSEN1, and PSEN2 mutations in early-onset Alzheimer disease: A genetic screening study of familial and sporadic cases. PLoS Med (2017) 0.75
Ethical challenges in preclinical Alzheimer's disease observational studies and trials: Results of the Barcelona summit. Alzheimers Dement (2016) 0.75
Primary and Secondary Prevention Trials in Alzheimer Disease: Looking Back, Moving Forward. Curr Alzheimer Res (2016) 0.75
Toward precision medicine in Alzheimer's disease. Ann Transl Med (2016) 0.75
An intranasally delivered peptide drug ameliorates cognitive decline in Alzheimer transgenic mice. EMBO Mol Med (2017) 0.75
Near-infrared spectroscopy (NIRS) and vagus somatosensory evoked potentials (VSEP) in the early diagnosis of Alzheimer's disease: rationale, design, methods, and first baseline data of the Vogel study. J Neural Transm (Vienna) (2017) 0.75
Decreased body mass index in the preclinical stage of autosomal dominant Alzheimer's disease. Sci Rep (2017) 0.75
The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement (2011) 24.26
Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement (2011) 24.02
The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement (2011) 21.80
Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med (2012) 14.14
Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults. Arch Neurol (2007) 10.75
Tangles and plaques in nondemented aging and "preclinical" Alzheimer's disease. Ann Neurol (1999) 10.45
Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol (2013) 9.43
Neuropathology of older persons without cognitive impairment from two community-based studies. Neurology (2006) 8.97
Profound loss of layer II entorhinal cortex neurons occurs in very mild Alzheimer's disease. J Neurosci (1996) 7.19
Neuropathology of cognitively normal elderly. J Neuropathol Exp Neurol (2003) 5.17
Alzheimer's disease: the challenge of the second century. Sci Transl Med (2011) 4.88
Alzheimer disease in the United States (2010-2050) estimated using the 2010 census. Neurology (2013) 4.80
Pittsburgh compound B imaging and prediction of progression from cognitive normality to symptomatic Alzheimer disease. Arch Neurol (2009) 4.55
Longitudinal assessment of Aβ and cognition in aging and Alzheimer disease. Ann Neurol (2011) 4.38
Neuropathology of nondemented aging: presumptive evidence for preclinical Alzheimer disease. Neurobiol Aging (2009) 4.36
Alzheimer's disease and Parkinson's disease. N Engl J Med (2003) 3.88
Neuron number in the entorhinal cortex and CA1 in preclinical Alzheimer disease. Arch Neurol (2001) 3.80
Testing the right target and right drug at the right stage. Sci Transl Med (2011) 3.55
Brain imaging and fluid biomarker analysis in young adults at genetic risk for autosomal dominant Alzheimer's disease in the presenilin 1 E280A kindred: a case-control study. Lancet Neurol (2012) 3.48
Clinical features of early-onset Alzheimer disease in a large kindred with an E280A presenilin-1 mutation. JAMA (1997) 2.81
Alzheimer's Prevention Initiative: a plan to accelerate the evaluation of presymptomatic treatments. J Alzheimers Dis (2011) 2.78
Florbetapir PET analysis of amyloid-β deposition in the presenilin 1 E280A autosomal dominant Alzheimer's disease kindred: a cross-sectional study. Lancet Neurol (2012) 2.65
Autosomal-dominant Alzheimer's disease: a review and proposal for the prevention of Alzheimer's disease. Alzheimers Res Ther (2011) 2.51
Neurotoxicity of Alzheimer's disease Aβ peptides is induced by small changes in the Aβ42 to Aβ40 ratio. EMBO J (2010) 2.26
Hypometabolism exceeds atrophy in presymptomatic early-onset familial Alzheimer's disease. J Nucl Med (2006) 2.17
Locus-specific mutation databases for neurodegenerative brain diseases. Hum Mutat (2012) 2.17
Novel presenilin 1 mutation (S170F) causing Alzheimer disease with Lewy bodies in the third decade of life. Arch Neurol (2005) 2.11
Developing an international network for Alzheimer research: The Dominantly Inherited Alzheimer Network. Clin Investig (Lond) (2012) 1.90
Presymptomatic cognitive deficits in individuals at risk of familial Alzheimer's disease. A longitudinal prospective study. Brain (1998) 1.63
Can we prevent Alzheimer's disease? Secondary "prevention" trials in Alzheimer's disease. Alzheimers Dement (2013) 1.38
Acceleration of cortical thinning in familial Alzheimer's disease. Neurobiol Aging (2009) 1.18
Comparison of symptomatic and asymptomatic persons with Alzheimer disease neuropathology. Neurology (2013) 1.10
The French series of autosomal dominant early onset Alzheimer's disease cases: mutation spectrum and cerebrospinal fluid biomarkers. J Alzheimers Dis (2012) 1.03
Familial Alzheimer's disease: site of mutation influences clinical phenotype. Ann Neurol (2000) 1.03
What the study of persons at risk for familial Alzheimer's disease can tell us about the earliest stages of the disorder: a review. J Geriatr Psychiatry Neurol (2005) 0.98
Measuring target effect of proposed disease-modifying therapies in Alzheimer's disease. Neurotherapeutics (2008) 0.97
Age of onset in familial early onset Alzheimer's disease correlates with genetic aetiology. Am J Med Genet (1993) 0.85
"Will I get Alzheimer disease?" when cognitively normal patients ask to be tested for Alzheimer disease. Continuum (Minneap Minn) (2013) 0.78